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Purpose: The purpose of this prospective study was to evaluate the efﬁ  cacy in intraocular 
pressure (IOP) control and the tolerance of a topically administered ﬁ  xed combination of timolol–
brimonidine in 50 patients with ocular hypertension and primary open-angle glaucoma.
Methods: After determining a baseline IOP, the ﬁ  xed combination timolol–brimonidine 
was used twice daily for two months, while IOP, ophthalmic signs, and/or symptoms were 
monitored.
Results: The mean IOP value was decreased from 23.09 mm Hg (±1.98 SD) to 17.46 mm Hg 
(±1.47 SD) during the 1st month (paired Student’s t test = 9.88 και p  0.001), and to 
17.51 mm Hg (±1.43 SD) in the 2nd month. Between the 1st and 2nd month, no statistical differ-
ence was observed (paired Student’s t test = 0.02 και p  0.1). In 8% of the patients during the 
1st month and 10% of patients in the 2nd month, some ophthalmic signs were observed, while 
only mild ophthalmic symptoms were reported in 6% and 8% of the patients, respectively.
Conclusions: In conclusion, the ﬁ  xed combination of timolol–brimonidine has a satisfactory 
IOP-lowering effect without any serious side effects due to the topical use.
Keywords: ﬁ  xed combination 0.2% brimonidine–0.5% timolol, ocular hypertension, primary 
open-angle glaucoma
Introduction
Intraocular pressure (IOP) is the most important prognostic risk factor, associated with 
the gradual vision loss in glaucoma.1,2 Lowering IOP has been proved to contribute 
effectively in delaying the development of glaucoma in patients with ocular hyperten-
sion, and also in delaying the progression of established glaucoma.3
The medications already in use decrease the IOP effectively, giving the opportunity 
to achieve the target IOP even with monotherapy. Nevertheless, many patients with 
glaucoma do not reach target IOPs with only one medication, which makes necessary 
the introduction of a second or even a third IOP-lowering drug. According to the Ocular 
Hypertension Treatment Study, after ﬁ  ve years of IOP-lowering medical treatment, 
40% of the patients need at least two drugs for effective IOP control.
Beta-adrenergic antagonists and alpha-adrenergic agonists are two commonly 
used categories of IOP-lowering medications. Timolol is a nonselective β-blocker, 
which lowers IOP by decreasing aqueous humor production, and brimonidine is an 
α-agonist which has a double action by decreasing aqueous humor production and, 
also, by increasing aqueous humor outﬂ  ow via the uveoscleral pathway. Various studies 
demonstrated a greater decrease in IOP with the ﬁ  xed combination timolol–brimonidine 
compared with the use of each drug separately.5–8 The purpose of this study is to Clinical Ophthalmology 2009:3 228
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evaluate the efﬁ  cacy of timolol–brimonidine in controlling 
IOP and its tolerance in patients with ocular hypertension 
and primary open-angle glaucoma (POAG).
Methods
Patients
This study evaluates the efﬁ  cacy and tolerance of the ﬁ  xed 
combination timolol–brimonidine in patients with ocular 
hypertension and POAG. For this purpose a two-month 
prospective study was conducted at the 1st University Eye 
Clinic of Athens.
Eligible patients had to have POAG or ocular hyperten-
sion and should have no prior antihypertensive medical 
treatment or only monotherapy. Key exclusion criteria 
included:
  1.  Active ocular infection or inﬂ  ammation
  2.  Previous sensitivity to timolol or brimonidine
  3.  Unstable heart disease that could be negatively affected 
from the use of the β-blocker
  4.  History of dendritic ulcer, bullous keratopathy, or active 
corneal ulcer in the past three months
  5. Corneal abnormalities that interfere with an accurate 
IOP measurement (eg, pterygium)
  6.  Retinal disease (eg, previous retinal detachment, diabetic 
retinopathy, or any other progressive disease)
  7.  Uses contact lens
  8.  Previous intraocular surgery or laser trabeculoplasty
  9.  Angle closure or secondary glaucoma
10.  Disease processes such as blepharitis/chronic conjunc-
tivitis.
The study was conducted in compliance with the Declara-
tion of Helsinki (1996) and in accordance with institutional 
review board regulations. Each participating investigator 
received institutional review board approval and obtained 
written informed consent from patients before initiation of 
the study.
Intervention
The study was conducted at the following phases. At the 
beginning, took place a baseline examination in order to 
classify patients according to the aforementioned criteria, an 
IOP measurement and a detailed medical history.
Patients who didn’t receive any medication had a baseline 
IOP measurement.
Patients already on medication at the baseline examina-
tion underwent a wash-out period followed by the base-
line IOP measurement. Wash-out periods, according to the 
previous drug, were determined as:
•  β-blockers: two weeks
•  α-agonists: one week
•  prostaglandin analogs: one week
•  topical carbonic anhydrase inhibitors: one week
The baseline IOP measurement included a measurement 
in the morning, before 11 AM on two different days of the 
same week. The mean IOP of these measurements was con-
sidered as the baseline IOP and was used for comparison 
of the results. At the same time a slit lamp and a fundus 
examination took place.
Afterwards, the ﬁ  xed combination timolol–brimonidine 
was given and the dosage was determined as one drop every 
12 hours at 8 AM and 8 PM.
Follow-up study visits were scheduled one and two 
months after the initiation of therapy. During the follow-up 
examination, IOP measurement was performed approxi-
mately at the same time (11 AM), three hours after drug 
instillation.
Variables that were evaluated, were ophthalmic signs 
evaluated under a slit lamp (conjunctival secretions, examina-
tion of the conjunctiva and corneal epithelium), and tolerance 
of the drug (pain, burning, stinging).
Results
Patient ages varied from 39 to 83 years and the mean age 
was 63.5 years. Fifty patients were recruited: 26 were men 
and 24 women. Six patients had no prior antihypertensive 
treatment and 44 were already on medication which is shown 
in Table 1.
Forty-six patients completed the study. Four patients 
discontinued treatment for the following reasons: topical 
adverse events in one patient who developed epithelial 
damage of the cornea and blurring of vision, and uncontrolled 
IOP in three patients. Patients who discontinued treatment 
Table 1 Intraocular pressure-lowering drugs used before initiation of 
the ﬁ  xed combination timolol–brimonidine and their percentage
Medication No of patients (%)
No medication 6 12%
Brimonidine 3 6%
Timolol 5 10%
Latanoprost 7 14%
Travoprost 2 4%
Bimatoprost 2 4%
Dorzolamide 2 4%
Timolol/Dorzolamide 14 28%
Latanoprost/Timolol 9 18%
Total 50  Clinical Ophthalmology 2009:3 229
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were included in data analysis with the measurements taken 
until the time of withdrawal.
Intraocular pressure
In order to verify the wash-out effect in the group of patients 
with prior antihypertensive treatment, we compared the mean 
IOP at the baseline examination before the wash-out period 
(19.61 mmHg ± 1.53 SD) with the mean IOP after this period 
(22.68 mmHg, ±1.71 SD). The statistical analysis showed 
a signiﬁ  cant difference (paired Student`s t test = 5.86 and 
p = 0.001).
The baseline mean IOP decreased from 23.09 mmHg 
(±1.98 SD) to 17.46 mmHg (±1.47 SD) at the 1st month 
examination. The statistical analysis showed a signiﬁ  cant 
difference (paired Student`s t test = 9.88 and p  0.001). At 
the 2nd month examination the mean IOP was 17.51 mmHg 
(±1.43 SD) and the statistical analysis demonstrated no 
signiﬁ  cant difference between the 1st and 2nd month (paired 
Student`s t test = 0.02 and p  0.1). Figure 1 shows the 
variation of IOP.
Tolerance
The evaluation of the drug tolerance included patient symp-
toms and slit lamp examination at the baseline examination 
and at the end of the 1st and 2nd months.
With the slit lamp examination, particular attention was 
given to the cornea, conjunctiva, and presence of secretions. 
Among the 50 patients, four in the 1st month (8%) and ﬁ  ve 
in the 2nd month (10%) presented with an ophthalmic sign, 
which is given in detail in Table 2. We note that certain 
patients presented with more than one ophthalmic sign.
During the follow-up visits, the patients completed a ques-
tionnaire about the appearance of symptoms such as sting-
ing, burning, pain and their classiﬁ  cation as mild, moderate, 
and serious. None of the 50 patients mentioned any moderate 
or serious symptom during the follow-up visits. Three 
patients at the end of the 1st month (6%) and four patients 
at the end of the 2nd month (8%) mentioned mild symptoms 
(Table 3). It should be mentioned that no patient reported 
pain at the end of the 2nd month.
Discussion
This study showed that there is a statistically signiﬁ  cant 
difference of the IOP before and after the initiation of the ﬁ  xed 
combination timolol–brimonidine in our group of patients, 
not related to their prior antihypertensive treatment. The mean 
baseline IOP decreased from 23.09 mmHg (±1.98 SD) to 
17.46 mmHg (±1.47 SD) at the end of the 1st month. There 
have been similar results of the IOP-lowering effect in other 
studies investigating the effect of the ﬁ  xed combination 
timolol–brimonidine vs brimonidine alone, vs a β-blocker, 
or vs the ﬁ  xed combination dorzolamide–timolol.5–10 Our 
study agrees with all these relevant studies on the fact that 
the ﬁ  xed combination timolol–brimonidine twice daily offers 
a better control of IOP in cases of ocular hypertension and 
POAG when compared with a monotherapy. An important 
factor contributing to the more efﬁ  cient IOP control with 
this ﬁ  xed combination could be that the dosage, twice daily, 
results in better patient compliance. This would be more 
difﬁ  cult with the use of two different eyedrops, each one of 
them given twice daily.
In addition, only four patients at the 1st month (8%) and 
ﬁ  ve at the 2nd (10%) presented with an ophthalmic sign and 
none had a moderate or serious symptom during the follow-
up visits. In contrast, the incidence of adverse events is higher 
with the use of timolol and brimonidine separately and often 
Table 2 Number of eyes that presented the speciﬁ  c sign at the 
1st and/or 2nd month, with no prior involvement
Ophthalmic signs 1st month 2nd month
Conjunctival secretions 3 3
Conjunctiva 4 4
Corneal epithelial disease 1 0
Total number of patients 4* 5**
Notes: *One patient had three signs and one patient had two signs; **Two patients 
had two signs.
Table 3 Eyes that presented with symptoms at 1st and 2nd month, 
but were not present at the baseline examination
Months Stinging Burning Pain
1st month 2 0 1
2nd month 2 2 0
23.09
17.46
17.51
0
5
10
15
20
25
Baseline 1st month 2nd month
IOP mm Hg
Figure 1 Mean intraocular pressure (IOP) change.Clinical Ophthalmology 2009:3 230
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leads to discontinuation of treatment.5,6 Conclusively, we 
postulate a signiﬁ  cant safety limit with the use of the ﬁ  xed 
combination timolol–brimonidine and, also, a low incidence 
of adverse events. This is in accordance with the current 
literature and recent studies.5,6,11
Conclusions
The ﬁ  xed combination timolol–brimonidine is administered 
twice daily and exhibits a signiﬁ  cant IOP-lowering effect 
compared with any previous antihypertensive treatment. 
Also, its topical use isn’t associated with any serious side 
effects which results in high safety and better patient compli-
ance with this speciﬁ  c antihypertensive treatment.
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